+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID04614480

Study Comparing Complex Versus Simple Exome Analysis to Guide Treatment Decisions in Patients with Advanced or Metastatic Solid Tumors

Led by Centre Georges Francois Leclerc · Updated on 2025-09-22

7976

Participants Needed

12

Research Sites

208 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the clinical benefit of a complex exome analysis compared to a simple exome analysis for patients with metastatic or locally advanced solid tumors. The study focuses on patients starting their first line of treatment and aims to determine whether the additional genetic information from the complex analysis can guide therapy decisions that would not be possible with the simple analysis. This Phase 2, multicenter study explores how advanced DNA analysis might impact precision medicine in cancer treatment. The study involves performing exome analysis on tumor DNA and constitutional DNA from patients undergoing first-line treatment for their metastatic or locally advanced cancer. The complex analysis provides detailed structural DNA data, including mutational signatures, tumor mutational load, and gene amplifications, which could influence treatment choices. The simple analysis looks at somatic and constitutional mutations without this additional information. The trial does not randomize participants and includes multiple cancer types such as breast, prostate, lung, colorectal, ovarian, sarcoma, and others. Participants will have tumor material available for analysis and will undergo blood tests and assessments according to the study protocol. Researchers will measure the proportion of patients whose therapy is initiated based on information from the complex exome analysis. Patients must have an expected life expectancy of at least six months and be able to follow study procedures. The study includes monitoring clinical outcomes related to treatment decisions guided by genetic findings. Participation continues as per the study timeline, with safety and efficacy assessed through these molecular insights.

CONDITIONS

Brief Title

Exome Analysis (Complexe vs Simple) to Help the Therapeutic Decision for the Precision Medicine

Research Team

F

François Ghiringhelli, PU-PH

E

Emilie Rederstorff, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here